Amivantamab-Vmjw (Intravenous Route)

Description and Brand Names

Drug information provided by: Merative, Micromedex®

US Brand Name

1. Rybrevant

Descriptions

Amivantamab-vmjw injection is used in combination with lazertinib as a first-line treatment for metastatic (cancer that has spread) or locally advanced (cannot be removed by surgery) non-small cell lung cancer (NSCLC) in patients who have an abnormal epidermal growth factor receptor (EGFR) gene (exon 19 deletions or exon 21 L858R substitution mutations). It is also used in combination with carboplatin and pemetrexed as a first-line treatment for metastatic or locally advanced NSCLC in patients who have an abnormal EGFR gene (exon 20 insertion mutations). This medicine is also used alone to treat metastatic or locally advanced NSCLC in patients who have an abnormal EGFR gene (exon 20 insertion mutations) and have received other cancer medicines (eg, platinum) but did not work well. Your doctor will perform a test before you take this medicine.

This medicine is to be given only by or under the supervision of your doctor.

This product is available in the following dosage forms:

• Solution